Skip to main content

letter

. 1990 Mar;29(3):369–370. doi: 10.1111/j.1365-2125.1990.tb03651.x

The acute toxic effect of the phosphodiesterase inhibitor rolipram on plasma osmolality.

I Sturgess, G F Searle

PMCID: PMC1380141 PMID: 2155639

369

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Lugnier C., Schoeffter P., Le Bec A., Strouthou E., Stoclet J. C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol. 1986 May 15;35(10):1743–1751. doi: 10.1016/0006-2952(86)90333-3. [DOI] [PubMed] [Google Scholar]
Ohzeki T. Urinary adenosine 3',5'-monophosphate (cAMP) response to antidiuretic hormone in diabetes insipidus (DI): comparison between congenital nephrogenic DI type 1 and 2, and vasopressin sensitive DI. Acta Endocrinol (Copenh) 1985 Apr;108(4):485–490. doi: 10.1530/acta.0.1080485. [DOI] [PubMed] [Google Scholar]
Uretsky B. F., Generalovich T., Verbalis J. G., Valdes A. M., Reddy P. S. Comparative hemodynamic and hormonal response of enoximone and dobutamine in severe congestive heart failure. Am J Cardiol. 1986 Jul 1;58(1):110–116. doi: 10.1016/0002-9149(86)90252-3. [DOI] [PubMed] [Google Scholar]
Weishaar R. E., Cain M. H., Bristol J. A. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537–545. doi: 10.1021/jm50001a001. [DOI] [PubMed] [Google Scholar]
Zeller E., Stief H. J., Pflug B., Sastre-y-Hernández M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry. 1984 Nov;17(6):188–190. doi: 10.1055/s-2007-1017435. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES